Brief: Rocket Pharmaceuticals Receives FDA Fast Track For RP-A601 Gene Therapy
08/06/2023 14:37
June 8 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O :
* ROCKET PHARMACEUTICALS RECEIVES FDA FAST TRACK AND ORPHAN
DRUG
DESIGNATIONS FOR RP-A601 GENE THERAPY FOR PKP2 ARRHYTHMOGENIC
CARDIOMYOPATHY (ACM)
Source text for Eikon: ID:nBw5ZyTcXa
Further company coverage: RCKT.O
(Reuters.briefs@thomsonreuters.com)
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08